Life Sciences and Healthcare

9 Ways Payers May be Impacted by Vertical Integration

The transformation of the healthcare delivery model and the reinvention of the PBMs will have implications for payers – what are the threats and opportunities? The below post is an excerpt from our white paper Beyond the PBM: A New Order for Healthcare Delivery.    Vertical integration giving PBMs a bigger role in the healthcare value […]

IDNs’ Continued Displacement of Traditional Insurers

Partners, Harvard Pilgrim Negotiations Underscore Growing Trend Amid continued merger mania in the U.S. healthcare industry, the news that integrated delivery titan Partners HealthCare is exploring a merger with innovative New England insurer Harvard Pilgrim Health Care stands out. The deal would not only add to a collection of tie-ups that are blurring the industry’s […]

Medicare Advantage leader eyes 50 percent penetration — but when?

Evaluating UnitedHealth’s Managed Medicare Prediction Among the key takeaways from UnitedHealth Group’s first quarter earnings call was a prediction that the market penetration of managed Medicare plans will reach 50 percent, up from roughly one-third today. This is at least the second time in the past year that a UnitedHealth official has staked that claim, […]

IV acetaminophen: Is it worth the cost?

In the midst of the opioid epidemic, hospitals and health systems are constantly looking for ways to alleviate pain that minimize opioid use. Acetaminophen remains a viable alternative, though organizations are making a concerted effort to restrict its intravenous use and promote oral administration. All of this started when IV acetaminophen was approved by the […]

Novo Nordisk’s Ozempic: Launch was late but sales forecasts climbing

This article is part of an ongoing blog series profiling the12 new, game-changing drugs predicted to achieve blockbuster status by 2022 in the 2018 edition of Drugs to Watch, the annual industry forecast and analysis from Clarivate Analytics. Read the full Drugs to Watch report here or follow the series for the latest updates. Drugs […]

Algeria, Morocco and Tunisia changing their regulatory landscape?

Algeria, Morocco and Tunisia have fantastic potential for development in the pharmaceutical sector but weaknesses in some aspects of the pharma regulatory system create barriers to market access. Conscious of this, regulatory authorities in the region say they are determined to improve regulatory processes to allow faster access to market for essential and innovative medicines. […]

Considering the impacts of the fasb’s new revenue recognition standards

New accounting standards issued by the Financial Accounting Standards Board will significantly alter how organizations recognize bad debt, though what that will mean for the revenue cycle is still uncertain. The rules took effect after December 15, 2017, for public healthcare entities and are set to take effect after December 15, 2018, for all others. […]

ESMO session explores CDK inhibition and cell cycle modulation in cancer

The principles of CDKs/cyclins in cell-cycle progression Deregulation of the cell cycle is a common feature of human cancer. The mammalian cell cycle is controlled by a subfamily of cyclin-dependent kinases (CDKs), the activity of which is modulated by several activators (cyclins) and inhibitors (INK4, and WAF1/KIP inhibitors). The activity of cell cycle CDKs is […]

Partnering to innovate creates ‘window of opportunity’ in biopharma sourcing and procurement

Partnership strategies are essential in driving value and performance in sourcing, procurement and supply management. Executives from Johnson & Johnson, Bristol-Myers Squibb and McKinsey & Company shared their experiences during the “Innovation in Sourcing and Procurement” educational session at DCAT Week ’18 in New York in March. Supplier collaboration is the next horizon with potential […]